ArticleFrontiers in medicine2026
Impact of immunosuppressive therapy and clinical risk factors on the prevalence of low bone mineral density in rheumatic diseases.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteoporosis is a severe comorbidity in inflammatory rheumatic diseases, impacting patient quality of life and healthcare costs. While general risk factors are known, the specific influence of various immunosuppressive therapies across different disease entities requires further characterization. This study aimed to determine the prevalence of low bone mineral density (BMD), identify clinical risk factors, and assess medication-associated factors in a large university cohort. Methods: A cross-sectional study of 704 adult patients receiving care at the specialized Rheumatology Outpatient Clinic of the Hannover Medical School was conducted. Data on lifestyle, medical history, and medication were collected via specialized questionnaires and electronic records. Low BMD was defined as a T-score ≤ -1.0. Statistical analyses included Pearson's chi-squared, Welch t-tests, and Wilcoxon rank-sum tests. Results: The prevalence of low BMD was 56%. Rheumatoid arthritis (RA) (65.8%) and systemic lupus erythematosus (SLE) (60.2%) showed the highest rates. Beyond age, female gender, and low BMI, alcohol consumption was significantly associated with low BMD across several diseases (RA: Conclusion: Patients with rheumatic diseases exhibit a substantial and clinically relevant prevalence of low BMD. Our findings highlight an association between alcohol consumption and low BMD. The association of specific csDMARDs likely reflects higher cumulative disease severity, necessitating intensified bone density monitoring in these treatment groups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.